BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24286594)

  • 1. Positron emission tomography/computed tomography for optimized colon cancer staging and follow up.
    Engelmann BE; Loft A; Kjær A; Nielsen HJ; Berthelsen AK; Binderup T; Brinch K; Brünner N; Gerds TA; Høyer-Hansen G; Kristensen MH; Kurt EY; Latocha JE; Lindblom G; Sloth C; Højgaard L
    Scand J Gastroenterol; 2014 Feb; 49(2):191-201. PubMed ID: 24286594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
    Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
    Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
    Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ
    Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels.
    Liu FY; Chen JS; Changchien CR; Yeh CY; Liu SH; Ho KC; Yen TC
    Dis Colon Rectum; 2005 Oct; 48(10):1900-12. PubMed ID: 15991059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
    Cochet A; Dygai-Cochet I; Riedinger JM; Humbert O; Berriolo-Riedinger A; Toubeau M; Guiu S; Coutant C; Coudert B; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):428-37. PubMed ID: 24196916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DIAGNOSTIC ROLE OF FLUORINE-18 (18F) FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY IN DETECTING RECURRENT DISEASE IN PATIENTS WITH COLORECTAL CANCER AND ELEVATED CARCINOEMBRYONIC ANTIGEN.
    Matovina E; Mihailović J; Nikoletić K; Srbovan D
    Med Pregl; 2015; 68(11-12):376-81. PubMed ID: 26939303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
    Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
    Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer.
    Ozis SE; Soydal C; Akyol C; Can N; Kucuk ON; Yagcı C; Erkek AB; Kuzu MA
    World J Surg Oncol; 2014 Feb; 12():26. PubMed ID: 24484935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.
    Chen SW; Hsieh TC; Yen KY; Yang SN; Wang YC; Chien CR; Liang JA; Kao CH
    Laryngoscope; 2014 Dec; 124(12):2732-8. PubMed ID: 25042474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
    Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
    Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma.
    Kubik-Huch RA; Dörffler W; von Schulthess GK; Marincek B; Köchli OR; Seifert B; Haller U; Steinert HC
    Eur Radiol; 2000; 10(5):761-7. PubMed ID: 10823629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
    Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
    J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.